Disparities in GLP-1 Receptor Agonist Use in Type 2 Diabetes
White and more affluent patients with type 2 diabetes are significantly more likely to receive GLP-1 receptor agonist therapy than individuals who are Black, Asian, Hispanic or low-income, a US study suggests.
Reuters Health Information
source https://www.medscape.com/viewarticle/966590?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/966590?src=rss
Comments
Post a Comment